How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) EPS for the quarter, missing analysts' consensus estimates of ($2.53) by $0.68. During the same period last year, the business earned ($1.69) earnings per share.

When did Arena Pharmaceuticals' stock split?

Arena Pharmaceuticals shares reverse split on the morning of Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Amit Munshi's approval rating as Arena Pharmaceuticals' CEO?

16 employees have rated Arena Pharmaceuticals Chief Executive Officer Amit Munshi on Glassdoor.com . Amit Munshi has an approval rating of 66% among the company's employees.

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD) , Inovio Pharmaceuticals (INO) , Cytokinetics (CYTK) , Micron Technology (MU) , NVIDIA (NVDA) , Novavax (NVAX) , Alibaba Group (BABA) , GW Pharmaceuticals (GWPH) and AT&T (T) .

NASDAQ:ARNA

Arena Pharmaceuticals (ARNA) Stock Price, News & Analysis

→ The #1 Investment of the Decade… (From Porter & Company) (Ad)

Free ARNA Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $99.99
▼
$99.99
50-Day Range: $93.13
▼
$99.99
52-Week Range: $45.50
▼
$100.00

Volume: 107 shs
Average Volume: 1.56 million shs
Market Capitalization: $6.17 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Arena Pharmaceuticals alerts:

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Arena Pharmaceuticals Stock (NASDAQ:ARNA)

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

ARNA Stock News Headlines

August 31, 2023 | uk.investing.com

Arwana Citramulia Tbk (ARNA)

August 21, 2023 | foxnews.com

MLS club places Bruce Arena on leave over probe into 'allegations of insensitive and inappropriate remarks'

April 16, 2024 | Porter & Company (Ad)

The #1 Investment of the Decade…

Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.

May 23, 2023 | bizjournals.com

RNA startup launches with $300M, Merck partnership

May 23, 2023 | seekingalpha.com

Longboard Pharmaceuticals: Undervalued Arena Spin-Out Has 2 Data Catalysts Due In 2023

May 6, 2023 | cnbc.com

Pfizer earnings and revenue top expectations despite Covid vaccine sales decline

April 25, 2023 | health.usnews.com

Arna L. Davidson

April 12, 2023 | foxnews.com

Portland, Maine, reopens basketball arena to migrants

April 16, 2024 | Porter & Company (Ad)

The #1 Investment of the Decade…

March 17, 2023 | forbes.com

Is Pfizer Stock Undervalued At $40?

February 9, 2023 | benzinga.com

Arna Marketing Group Continues Investing in State-of-the-art Canon Inkjet Technology to Deliver "The Arna Advantage"

February 8, 2023 | finance.yahoo.com

Arna Marketing Group Continues Investing in State-of-the-art Canon Inkjet Technology to Deliver “The Arna Advantage”

February 6, 2023 | msn.com

A DNA protein may be responsible for causing cancerous ‘stress balls’ in the body: U of S research

August 23, 2022 | thestreet.com

Obesity Drugs: The Road to Perdition

August 9, 2022 | baystreet.ca

Pfizer to Buy Global Blood Therapeutics

August 4, 2022 | forbes.com

Should You Buy Pfizer Stock After An Upbeat Q2?

June 29, 2022 | forbes.com

Should You Buy, Sell, Or Hold Pfizer Stock At $52?

May 3, 2022 | theglobeandmail.com

7 Biotech Stocks With Key Catalysts in March

March 10, 2022 | seekingalpha.com

Pfizer confirms HSR waiting period for Arena Pharmaceuticals deal expired

March 7, 2022 | seekingalpha.com

Arena Pharma gains after report Pfizer deal will clear without HSR second request

February 25, 2022 | seekingalpha.com

Arena Pharmaceuticals GAAP EPS of -$2.54 misses by $0.31

February 24, 2022 | msn.com

Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus

February 23, 2022 | uk.finance.yahoo.com

SFO opens criminal probe into collapse of Arena Television

February 23, 2022 | finance.yahoo.com

Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates

February 9, 2022 | finance.yahoo.com

Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23

February 9, 2022 | benzinga.com

HC Wainwright & Co. Downgrades Arena Pharmaceuticals to Neutral, Lowers Price Target to $100

February 9, 2022 | markets.businessinsider.com

Expert Ratings For Arena Pharmaceuticals

See More Headlines

Receive ARNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/15/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:ARNA
CUSIP: 04004710
CIK: 1080709
Web: www.arenapharm.com
Phone: (858) 453-7200
Fax: 858-453-7210
Employees: 448
Year Founded: 1977

Profitability

EPS (Most Recent Fiscal Year): ($10.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-616,430,000.00
Net Margins: N/A
Pretax Margin: -1,141,542.63%
Return on Equity: -69.83%
Return on Assets: -62.35%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 8.59
Quick Ratio: 8.59

Sales & Book Value

Annual Sales: $50,000.00
Price / Sales: 123,305.67
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.94 per share
Price / Book: 9.14

Miscellaneous

Outstanding Shares: 61,659,000
Free Float: 60,173,000
Market Cap: $6.17 billion
Optionable: Optionable
Beta: 0.55

Social Links

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Amit D. Munshi M.B.A. (Age 54)
Pres & CEO
Comp: $1.22M
Ms. Laurie D. Stelzer (Age 54)
Exec. VP & CFO
Comp: $630.76k
Mr. Vincent E. Aurentz (Age 54)
Exec. VP & Chief Bus. Officer
Comp: $692.82k
Dr. Christopher H. Cabell FACC
M.D., MHS, Advisor
Mr. Robert Lisicki (Age 54)
Exec. VP & Chief Commercial Officer
Comp: $686.63k
Dr. Douglas A. Bakan Ph.D.
Exec. VP of Technical Operations
Dr. Lamine Mbow Ph.D.
Sr. VP & Chief Scientific Officer
Megan E. Knight
Director of Investor Relations
Patrick Malloy
VP of Investor Relations & Corp. Communications
Mr. Michael E. Paolucci (Age 62)
Exec. VP of HR

Key Competitors

View All Competitors

ARNA Stock Analysis - Frequently Asked Questions

How were Arena Pharmaceuticals' earnings last quarter?: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) EPS for the quarter, missing analysts' consensus estimates of ($2.53) by $0.68. During the same period last year, the business earned ($1.69) earnings per share.
When did Arena Pharmaceuticals' stock split?: Arena Pharmaceuticals shares reverse split on the morning of Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What is Amit Munshi's approval rating as Arena Pharmaceuticals' CEO?: 16 employees have rated Arena Pharmaceuticals Chief Executive Officer Amit Munshi on Glassdoor.com. Amit Munshi has an approval rating of 66% among the company's employees.
What other stocks do shareholders of Arena Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals (GWPH) and AT&T (T).

This page (NASDAQ:ARNA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Arena Pharmaceuticals (ARNA) Stock Price, News & Analysis

About Arena Pharmaceuticals Stock (NASDAQ:ARNA)

ARNA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

ARNA Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info